Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gapicomine SCHEMBL1037773 | 0.85 | SLC2A4 (0.61) | GAASLC2A4ADRA2CALDH1A1CYP3A4 | |
| Gapicomine SCHEMBL6121683 | 0.82 | SLC2A4 (0.59) | GAASLC2A4ALDH1A1CYP3A4CYP2D6 | |
| Gapicomine SCHEMBL9336954 | 0.82 | SLC2A4 (0.59) | GAASLC2A4ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL10054983 | 0.82 | SLC2A4 (0.59) | GAASLC2A4ALDH1A1KDM4EGLA | |
| SCHEMBL3741348 | 0.82 | ALDH1A1 (0.50) | GAASLC2A4ALDH1A1KDM4EGLA | |
| SCHEMBL9180552 | 0.82 | LMNA (0.52) | ALDH1A1KDM4ENPSR1CYP2D6LMNA | |
| Cycloheptanamine SCHEMBL7486009 | 0.81 | MAPT (0.44) | GAASLC2A4KDM4EGLACYP3A4 | |
| Diethylamine SCHEMBL11141239 | 0.81 | RAB9A (0.48) | ALDH1A1KDM4ENPSR1CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL5395461 | 0.80 | ALDH1A1 (0.49) | GAASLC2A4ALDH1A1KDM4EGLA | |
| SCHEMBL29444840 | 0.80 | MEN1 (0.56) | GAASLC2A4ALDH1A1KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 519 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| CN-118221424-B | Anti-skid and anti-fouling ceramic tile and preparation method thereof | 广东大角鹿新材料有限公司 | 2024-07-30 | — | — | CN | claimed |
| CN-118221424-A | Anti-skid and anti-fouling ceramic tile and preparation method thereof | 广东大角鹿新材料有限公司 | 2024-06-21 | — | — | CN | claimed |
| US-20240154124-A1 | NEGATIVE ELECTRODE PLATE AND LITHIUM-ION BATTERY COMPRISING SAME | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2024-05-09 | — | — | US | claimed |
| CN-117751935-A | Composition containing fluroxypyr meptyl ester | 安徽省四达农药化工有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-117624031-A | Preparation method of 4- (ethylaminomethyl) pyridine | 安徽华邦药业有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-117362219-A | Preparation method of 4- (ethylaminomethyl) pyridine | 南京法恩化学有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-117362220-A | Preparation method of topiramate | 南京法恩化学有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-115210339-A | Etching solution for titanium nitride and molybdenum conductive metal wires | 弗萨姆材料美国有限责任公司 | 2022-10-18 | — | — | CN | claimed |
| CN-103159672-A | Preparation method of tropine amide | HUNAN IVEN BIO TECHNOLOGY CO LTD | 2013-06-19 | — | — | CN | claimed |
| WO-2004108068-A2 | 4-[4-(4-MORPHOLINO)ANILINO]PYRIMIDINE DERIVATIVES, METHOD FOR PREPARING THEREOF AND ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | B & C BIOPHARM CO., LTD. (KR) | 2004-12-16 | — | — | WO | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| CN-1440401-A | Amino substituted dibenzothiophene derivatives for treatmnt of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2003-09-03 | — | — | CN | claimed |
| EP-1155001-A4 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | LION BIOSCIENCE AG (DE) | 2003-05-28 | — | — | EP | claimed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| US-6479492-B1 | TREATMENT OF INFLAMMATORY DISEASES IN A MAMMALIAN PATIENT | ELAN PHARMACEUTICALS, INC. | 2002-11-12 | — | — | US | claimed |
| US-6417195-B1 | LIBRARIES AND COMBINATORIAL CHEMISTRY | LION BIOSCIENCE AG (DE) | 2002-07-09 | — | — | US | claimed |
| EP-1155001-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 2001-11-21 | — | — | EP | claimed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | claimed |
| WO-2000050406-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | LION BIOSCIENCE AG (DE) | 2000-08-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | GAA 3522/4885SLC2A4 1661/4885ADRA2C 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.